Navigation Links
New Hope to Beat Cancer
Date:3/12/2009

Aurora St. Luke's is one of a few institutions in the world to offer skin cancer clinical trial.

MILWAUKEE, March 12 /PRNewswire/ -- Aurora St. Luke's Medical Center is one of the first institutions in the world to offer a new skin cancer research study that trains the patient's immune system to kill cancer cells.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090303/CG78204LOGO-b)

The Young Tumor-Infiltrating Lymphocyte (Y-TIL) trial is a phase 2 clinical trial being offered with technical support from the National Cancer Institute (NCI) in Bethesda, Md. Milwaukee native Jeff Capstran participated in an earlier stage of this trial at NCI. Capstran had stage-four metastatic melanoma, a diagnosis that few survive, but with small kids at home he was determined to find treatment options.

"I knew that my illness was very serious, but there had to be new opportunities to fight back," Capstran says. "When I found out about the study at NCI, I knew I had to jump at the chance. Today, I am cancer free."

The early results from a similar trial at the NCI are exciting for patients with stage-four metastatic melanoma. Published reports for the trial show a 51 percent response rate.

To qualify, all patients must be diagnosed with stage-four metastatic melanoma. During the trial blood is drawn from the patient, along with a sample of the tumor. The T cells, which are the immune system's killer cells, are extracted from the tumor and re-educated to attack the cancer cells. The patient's normal immune system is then temporarily suppressed using chemotherapy, and the newly trained T cells are returned to the patient. The T cells are expected to survive, replicate and kill the cancer.

The trial has a capacity for 75 patients over a three-year period. Of those 41 are expected to qualify for the entire process. With the success of this program, the next step is a phase 3 trial where hundreds of patients would be enrolled and treated.

Due to the experimental features of this clinical trial, some portions of the study may not be covered by health insurance. As a not-for-profit, Aurora Health Care's philanthropy program has secured more than $2 million in support from outside donors, including $50,000 from Anne's Hope Foundation.

Milwaukee's own Northwestern Mutual Foundation has made its largest health care donation of $750,000 to Aurora's immunotherapy program, which has oversight of the Y-TIL Trial. Other contributors include A. Elser, Jr., William Schuett, Sr., Stella Jones and Sherwood and Libby Temkin.

To keep the trial affordable for all who participate, an additional $700,000 in donations is being sought for each year of the program, a total of over $2,000,000.

Aurora Health Care is a not-for-profit Wisconsin health care provider and a national leader in efforts to improve the quality of care. Aurora provides care at sites in more than 90 communities throughout eastern Wisconsin and Illinois.

Online newsroom: www.Aurora.org/Newsroom

Clinical trial information: www.aurora.org/y-til


'/>"/>
SOURCE Aurora Health Care
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. Novel Technology Breaks Through Cancer Pain
8. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
9. Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... YORK , Jan. 19, 2017 Report ... ... 2016-2026: Opportunities for Leading Companies – our new study ... report discusses issues and events affecting the Alzheimer,s disease ... analyses to answer these key questions: - How is ...
(Date:1/19/2017)... 2017 According to a study conducted by ... to witness a CAGR of 6.5% during the forecast period 2016-2024. ... continue to be the leading market for cryotherapy globally during the ... Highlights ... ensuring affordable and adequate supply of gas in order to provide ...
(Date:1/19/2017)... -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the German ... Germany , has purchased a MRIdian ... Clinic Heidelberg as part of its initiative for MRI-based ... be headed by Medical Director and Professor Jürgen Debus, ... German Cancer Research Center (DKFZ), the Heidelberg Heavy Ion ...
Breaking Medicine Technology:
(Date:1/21/2017)... ... January 21, 2017 , ... In the United States, 20 million women and ... recovery, they often feel shame for having struggled with an eating disorder as well ... workshop, “Rising Strong in Life After an Eating Disorder” -- to be featured at ...
(Date:1/20/2017)... ... ... A new partnership between Goodwill® and Roadie, Inc. aims to make it easier ... couches to dressers and bicycles. Roadie — the national on-the-way delivery network — will ... through February 28th. , “January is an exciting time when resolutions are made ...
(Date:1/20/2017)... ... , ... Doctor C LLC, a company based out of Arizona that focuses ... the marketing and distribution of its product, The Right C. , The Right C ... than traditional vitamin C supplements. At the trade show, Doctor C had the opportunity ...
(Date:1/20/2017)... ... January 20, 2017 , ... ... enhance people’s everyday lives, recently attended the January ECRM Trade Show in Hilton ... is known for its large range of supplements that keep the body functioning ...
(Date:1/20/2017)... ... January 20, 2017 , ... "TransFlare 4K Mystique comes with 44 colorful ... Pro X," said Christina Austin - CEO of Pixel Film Studios. , TransFlare ... Sensor,TransFlare 4K Mystique lens flare and light leak transitions have a very high-dynamic range ...
Breaking Medicine News(10 mins):